Staley Capital Advisers Inc Blueprint Medicines Corp Transaction History

Staley Capital Advisers Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$54.1 - $110.08 $162,300 - $330,240	-3,000 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$57.09 - $79.27 $171,270 - $237,810	3,000 New	3,000 $234,000
Q1 2020 May 08, 2020	SELL	$48.11 - $82.22 $144,330 - $246,660	-3,000 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$48.7 - $86.6 $146,100 - $259,799	3,000 New	3,000 $240,000

8.67M

151K

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.73B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Staley Capital Advisers Inc, based on Form 13F filings with the SEC.

Stay updated on Staley Capital Advisers Inc with notifications on news.